EGYPTIAN-TOURISM
16.3.2023 14:11:45 CET | Business Wire | Press release
The most popular foreign destinations for British holidaymakers are Italy and Spain. However, what many travellers do not know: For the price they spend on a holiday in these countries, they could experience more luxury and adventure in Egypt.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230216005515/en/
Winter in Egypt (Photo: Business Wire)
What Brits pay for their holidays abroad
Brits love to travel, but how much do they actually spend on their holidays? According to National Institute of statistics (Ine), the British invested an average of £1,0001 per person on a trip in 2021. However, a one-week stay including meals in a three-star hotel in Italy, for example, can cost up to £1,300 even in the low season. And that doesn't even include sightseeing, theatre tickets or museum visits.
In Egypt, two people can spend seven nights in a five-star hotel for less than the average price of a holiday in an Italian coastal region - all-inclusive, of course. The return flight from a major UK city is also included here. This leaves a lot of the budget for excursions and activities.
From paradisiacal beaches to the impressive expanse of the desert
Egypt has a lot to offer for all travelers - whether they are sun worshippers looking to relax on the beautiful coasts or culture vultures in search of ancient sites steeped in history. "Over the past two years, when we had restrictions on travel due to the pandemic, Egypt has been improving its travel infrastructure and working to expand what it has to offer visitors," says Amr El-Kady, managing director of the Egyptian Tourism Authority. "Even tourists who have visited Egypt before will now be able to discover many new options for things to do and interesting things to see. There are numerous, fantastic new accommodations available as domiciles."
For beach and sea lovers, the entire Egyptian coast is an ideal destination. You'll find plenty of white sandy beaches and warm, crystal-clear waters on both the Mediterranean and the Red Sea. From the beach resorts in Sharm El Sheikh on the Sinai Peninsula and Hurghada on Egypt's east coast, you can enjoy breathtaking views over the Red Sea. From here, you can also explore the mystical mountain regions inland. The Red Sea is also home to some of the most beautiful coral reefs in the world and can be explored by both amateur and professional divers. The Mediterranean coast from Alexandria to Marsa Matruh also beckons with turquoise waters and seemingly endless sandy beaches that invite you to swim, dive and sunbathe.
Those who prefer to discover and enjoy the incomparable beauty of the desert will not be disappointed either and can expect an experience like from 1001 Nights. In the Sinai desert, hiking and camel safaris offer an unforgettable experience for outdoor enthusiasts.
Tradition and history in the cities of the pharaohs
Among the most impressive historical sites is the magnificent city of Luxor with its spectacular sights such as the Valley of the Kings, the Temple of Karnak, and the legendary Luxor Temple. For a special experience, take a hot air balloon ride for a majestic view of the city on the Nile from above.
Fans of city trips should have Cairo on their agenda: In the Egyptian capital, millennia-old relics of antiquity meet the modern culture of the Middle East. The Great Sphinx and the Pyramids of Giza - the only remaining wonder of the ancient world - are unique buildings and an impressive testimony to ancient architecture. The history of the country is also presented in detail in the Egyptian Museum: It houses over 120,000 artefacts, including the treasures from Tutankhamun's tomb.
The Khan El Khalili bazaar is one of the oldest and most famous markets in the Middle East: here, holidaymakers can not only find authentic souvenirs but also enjoy the specialties of the local cuisine and get to know contemporary Egyptian culture.
Anyone looking for a multifaceted, historical and affordable travel destination should try Egypt to see for themselves the rich variety of this country with their own eyes and senses.
1 Ine (2022) Gasto de los turistas internacionales segun pais de residencia. Taken from: https://www.ine.es/jaxiT3/Datos.htm?t=10838#!tabs-tabla
– ENDE –
For further information:
https://www.experienceegypt.eg/
About the Egyptian Tourism Board
The Egyptian Tourism Board, established in 1981, is a regulatory body affiliated with the Ministry of Tourism. Its mission is to stimulate international tourism by promoting Egypt's rich history and civilization and highlighting the country's many tourist attractions. It also aims to promote domestic tourism, raise awareness of tourism throughout the country and strengthen the link between Egyptians and their heritage.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230216005515/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
